Headache startup Slate Medicines raises $130 million to bring new migraine drug into clinic

Slate Medicines' antibody drug is designed to block PACAP, a protein associated with migraines. The Phase 1 asset has been licensed by China's DartsBio Pharmaceuticals.

The post Headache startup Slate Medicines is spending $130 million to bring new migraine drugs into clinics appeared first on MedCity News.